ATE147988T1 - Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände - Google Patents

Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände

Info

Publication number
ATE147988T1
ATE147988T1 AT91915377T AT91915377T ATE147988T1 AT E147988 T1 ATE147988 T1 AT E147988T1 AT 91915377 T AT91915377 T AT 91915377T AT 91915377 T AT91915377 T AT 91915377T AT E147988 T1 ATE147988 T1 AT E147988T1
Authority
AT
Austria
Prior art keywords
treatment
nutrients
product containing
pct
hypocaloric
Prior art date
Application number
AT91915377T
Other languages
English (en)
Inventor
Linda Fryklund
Peter Gluckman
Anna Skottner
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20380208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE147988(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Application granted granted Critical
Publication of ATE147988T1 publication Critical patent/ATE147988T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT91915377T 1990-08-24 1991-08-22 Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände ATE147988T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9002731A SE9002731D0 (sv) 1990-08-24 1990-08-24 Product comprising growth factor

Publications (1)

Publication Number Publication Date
ATE147988T1 true ATE147988T1 (de) 1997-02-15

Family

ID=20380208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915377T ATE147988T1 (de) 1990-08-24 1991-08-22 Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände

Country Status (14)

Country Link
US (1) US6034059A (de)
EP (1) EP0546007B2 (de)
JP (1) JP2521867B2 (de)
AT (1) ATE147988T1 (de)
AU (1) AU650050B2 (de)
CA (1) CA2088674A1 (de)
DE (1) DE69124382T3 (de)
DK (1) DK0546007T3 (de)
ES (1) ES2097816T5 (de)
GR (1) GR3022935T3 (de)
IE (1) IE912615A1 (de)
PT (1) PT98764B (de)
SE (1) SE9002731D0 (de)
WO (1) WO1992003154A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
WO2002043578A2 (en) * 2000-11-28 2002-06-06 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
JP3896879B2 (ja) * 2002-03-22 2007-03-22 日本電気株式会社 トラヒック監視システム
ES2532089T3 (es) * 2005-06-02 2015-03-24 Ipsen Biopharmaceuticals, Inc. GH e IGF-1 para el tratamiento de trastornos del crecimiento

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001038A1 (en) * 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
CA1320441C (en) * 1986-01-09 1993-07-20 Douglas W. Wilmore Use of growth hormone for nitrogen retention under hypocaloric conditions
DE3782737T3 (de) * 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
JP2507106B2 (ja) * 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド

Also Published As

Publication number Publication date
EP0546007B1 (de) 1997-01-22
WO1992003154A1 (en) 1992-03-05
PT98764A (pt) 1993-09-30
DE69124382T2 (de) 1997-06-26
DK0546007T3 (da) 1997-03-17
AU8448891A (en) 1992-03-17
IE912615A1 (en) 1992-02-26
SE9002731D0 (sv) 1990-08-24
EP0546007B2 (de) 2003-01-29
ES2097816T5 (es) 2003-07-16
JP2521867B2 (ja) 1996-08-07
GR3022935T3 (en) 1997-06-30
CA2088674A1 (en) 1992-02-25
DE69124382D1 (de) 1997-03-06
EP0546007A1 (de) 1993-06-16
AU650050B2 (en) 1994-06-09
US6034059A (en) 2000-03-07
JPH05509323A (ja) 1993-12-22
ES2097816T3 (es) 1997-04-16
DE69124382T3 (de) 2003-09-11
PT98764B (pt) 1999-01-29

Similar Documents

Publication Publication Date Title
DE69120430D1 (de) Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
DE69328550D1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
IL116385A (en) Sulphonamides their manufacture and pharmaceutical compositions containing them
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE126972T1 (de) Formulierung zur behandlung von silage.
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
ATE147988T1 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
DE69331546D1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
ATE64300T1 (de) Wirkstoffe zur anwendung bei der behandlung von tumoren.
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DE69531150D1 (de) Verwendung von biopolymeren zur behandlung der muskeln
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
UA40974A (uk) Спосіб лікування міопії у дітей та підлітків
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
DE3776662D1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
GR3027682T3 (en) 4-guanidinobutyramide for improving blood circulation.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties